Zhao Liwei, Liu Peng, Kepp Oliver, Kroemer Guido
Faculty of Medicine, University of Paris Sud, Kremlin-Bicêtre, France; Cell Biology and Metabolomics Platforms, Gustave Roussy Cancer Campus, Villejuif, France; Equipe 11 labellisée Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France; Equipe labellisée Ligue Nationale Contre le Cancer, Université Paris Descartes, Université Sorbonne Paris Cité, Université Paris Diderot, Institut National de la Santé et de la Recherche Médicale (INSERM), UMR1138, Centre de Recherche des Cordeliers, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Université Pierre et Marie Curie, Paris, France.
Faculty of Medicine, University of Paris Sud, Kremlin-Bicêtre, France; Cell Biology and Metabolomics Platforms, Gustave Roussy Cancer Campus, Villejuif, France; Equipe 11 labellisée Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France; Equipe labellisée Ligue Nationale Contre le Cancer, Université Paris Descartes, Université Sorbonne Paris Cité, Université Paris Diderot, Institut National de la Santé et de la Recherche Médicale (INSERM), UMR1138, Centre de Recherche des Cordeliers, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Université Pierre et Marie Curie, Paris, France.
Methods Enzymol. 2019;629:177-193. doi: 10.1016/bs.mie.2019.05.001. Epub 2019 May 27.
The exodus of the alarmin high mobility group box 1 (HMGB1) from the nucleus constitutes a crucial cellular danger signal and manifests as a sequential process in which HMGB1 first exits the nucleus into the cytoplasm and then is secreted or passively released through the permeabilized plasma membrane. Extracellular HMGB1 can interact with pattern recognition receptors to stimulate innate immune responses. Here, we describe a discovery pipeline for the identification of pharmacological agents endowed with HMGB1 releasing properties. The "retention using selective hooks" (RUSH) system in which a streptavidin-NLS3 fusion protein serves as a nuclear hook to sequester streptavidin-binding peptide (SBP) fused with HMGB1 and green fluorescent protein (GFP) allowed for synchronizing HMGB1 increase. Thus, exclusively in the presence of biotin, which liberates HMGB1-SBP-GFP from its nuclear hook, immunogenic cell death (ICD) inducers such as anthracyclines are able to cause the nucleo-cytoplasmic translocation of HMGB1-SBP-GFP. This system facilitates the identification of HMGB1 releasing agents in medium- to high-throughput screening assays.
警报素高迁移率族蛋白B1(HMGB1)从细胞核中流出构成了一种关键的细胞危险信号,并表现为一个连续的过程,即HMGB1首先从细胞核进入细胞质,然后通过通透的质膜被分泌或被动释放。细胞外HMGB1可与模式识别受体相互作用以刺激先天性免疫反应。在此,我们描述了一种用于鉴定具有HMGB1释放特性的药物制剂的发现流程。“使用选择性钩子保留”(RUSH)系统中,链霉亲和素-NLS3融合蛋白作为核钩子来螯合与HMGB1和绿色荧光蛋白(GFP)融合的链霉亲和素结合肽(SBP),从而实现HMGB1增加的同步化。因此,仅在生物素存在的情况下,生物素可将HMGB1-SBP-GFP从其核钩子中释放出来,蒽环类等免疫原性细胞死亡(ICD)诱导剂能够导致HMGB1-SBP-GFP的核质转运。该系统有助于在中高通量筛选试验中鉴定HMGB1释放剂。